Handelsavisen
prelaunch
Companies Healthcare BAJH.NS
BA
BAJH.NS NSE (India) Pharmaceuticals

Bajh.Ns

$292,80
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,31 %
Op margin
10,6 %
ROE
8,5 %
Net margin
7,3 %
Debt / equity
0,48
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

BAJH.NS operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

Business. BAJH.NS operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
8,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BAJH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BAJH.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    BAJH.NS operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    The company maintains a conservative capital structure with a debt-to-equity ratio of 0.48, below the industry median of 0.65, indicating a lower reliance on debt financing. Free cash flow of INR 565.5 million supports operational flexibility, though operating cash flow of INR 216.2 million is modest relative to total liabilities of INR 3.7 billion. The current ratio of 1.89 suggests adequate short-term liquidity, though the risk assessment flags net cash as negative after subtracting total debt.

    Profitability metrics show a return on equity of 8.47% and a return on assets of 4.74%, both below the industry median of 10.2% and 6.1%, respectively. Gross profit of INR 2.6 billion represents 47.2% of revenue, which is in line with the industry average, but operating income of INR 576.1 million reflects a 10.6% margin, below the median of 12.3%.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts. No material revenue is attributed to international markets, suggesting a domestic focus.

    Outlook data indicates a projected 12.3% year-over-year revenue growth for the current fiscal year, driven by new product launches and market expansion. The next fiscal year is expected to see a 9.8% growth, though this is slightly below the industry median of 11.5%. Historical revenue growth has averaged 8.7% annually over the past five years.

    Risk factors include medium liquidity risk due to the negative net cash position and a current ratio that, while acceptable, does not provide a large buffer against short-term obligations. Dilution risk is assessed as low, with no recent share issuance and no material dilution expected in the near term. No significant regulatory or geopolitical risks are currently flagged.

    Recent filings and transcripts have not disclosed any material events that would significantly alter the company's strategic direction or financial outlook.

    Key takeaways
    • BAJH.NS maintains a conservative capital structure with a debt-to-equity ratio of 0.48, below the industry median.
    • Return on equity of 8.47% and return on assets of 4.74% indicate below-median profitability.
    • Revenue is concentrated in a single business segment with no disclosed geographic diversification.
    • Outlook projects 12.3% revenue growth for the current fiscal year, driven by new product launches.
    • Liquidity risk is moderate due to a negative net cash position, though the current ratio remains acceptable.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $292,80
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $4.66B
    Net cash
    -$2.23B
    Current ratio
    1.9
    Debt / equity
    0.5
    ROA
    4.7%
    ROE
    8.5%
    Cash conversion
    55.0%
    CapEx / revenue
    -2.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin10,6 %Above median
    Net Margin7,3 %Above median
    ROE8,5 %Above median
    Capex / Rev-2,1 %Above median
    D/E0,48Below median
    Cash Conv0,55Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • BAJH.NS Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BAJH.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage